Pfizer's Ibrance Gets FDA Approval For Breast Cancer In Men

Pfizer's Ibrance Gets FDA Approval For Breast Cancer In Men

April 6, 2019 298

Pfizer, Inc.’s  blockbuster medicine Ibrance gained FDA approval for the treatment of breast cancer in men, thereby expanding the drug’s eligible patient population.

Ibrance, CDK 4/6 inhibitor, can now be prescribed in combination with an aromatase inhibitor or AstraZeneca’s Faslodex (fulvestrant) for the treatment of men with HR+, HER2- metastatic breast cancer. The approval for the expanded indication is based predominately on real-world data, a new approach to expanding the use of already approved innovative medicines.

Ibrance has been generating strong sales and is a key driver of the company’s top line. The drug generated sales of $4.1 billion in 2018. With the expanded label, the drug should bring in more sales

Shares of Pfizer have declined 2% so far this year against the industry’s 4.4% increase.

Ibrance is a key drug in Pfizer’s oncology portfolio. The company is exploring the possibility of expanding Ibrance into recurrent and subsequent early breast cancer as well as several non-breast cancer indications like pancreatic and head and neck cancers.

However, competition in the breast cancer market has risen with launch of Eli Lilly’s (NYSE:LLY) Verzenio and Novartis’ (NYSE:NVS) Kisqali in the past couple of years. Nonetheless, in key markets like the United States, Europe and Japan, Ibrance has maintained greater than 90% share of total CDK inhibitors class volume despite rising competition,.

Pfizer currently carries a Zacks Rank #4 (Sell).

Zacks' Top 10 Stocks for 2019

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?

Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.

 

 

 

Information source: https://www.investing.com/analysis/pfizers-ibrance-gets-fda-approval-for-breast-cancer-in-men-200404429

Block ?

If this page is in your subscriptions, then it will be removed. You will not see this page. If you want to unblock a user, go to the settings, the list of blocked users and click unblock

Complain

The user will not know who exactly sent the complaint

Delete Company

The user will not know who exactly sent the complaint

Notifications

You Have 112 readed notifications

CHATS

Select chat category

×